ERBB2 and breast carcinoma: The results showing that the targeting moiety enhanced cellular uptake in HER2-overexpressing BT-474 breast cancer cells inspired this author to adopt the same coupling strategy to engineer anti-HER2 CB11-modified cationic SLN for site-specific delivery of perillaldehyde 1,2-epoxide [37].